Comparison of high sensitive c reactive protein levels between metabolically healthy and unhealthy obese
DOI:
https://doi.org/10.36216/jpd.v8i1.235Keywords:
hs-CRP, MHO, MUHOAbstract
Introduction: Overweight and obesity are associated with risks of several comorbidities, yet not all individuals with obesity condition having equal metabolic risks, suggesting the presence of a subgroup known as metabolically healthy obese (MHO) and metabolically unhealthy obese (MUHO). Obesity is characterized by chronic low-grade inflammation, with C-reactive Protein (CRP) serving as a key inflammatory marker. Research on high-sensitivity CRP (hs-CRP) levels across different obesity categories, especially MHO and MUHO, remains limited.
Aim: This study aims to compare hs-CRP levels across various levels of obesity, particularly in MHO and MUHO individuals.
Methods: This analytical cross-sectional study included subjects aged 18-60 from Denpasar with a BMI over 25 kg/m2. Subjects with chronic or acute inflammatory conditions were excluded. Comparative tests were utilized for analysis.
Results: The study comprised 40 men and 20 women with an average age of 35.6 years. Of these, 35% were classified as MHO and 65% as MUHO. The analysis revealed no significant difference in hs-CRP levels between the MHO and MUHO groups (p = 0.108), likely due to similar age and BMI distributions resulting in comparable levels of inflammation.
Conclusion: The analysis demonstrated no significant variation in hs-CRP levels between MHO and MUHO groups.
Downloads
References
Garvey, W.T., Garber, A.J., Mechanick, Bray, G.A., Dagogo-Jack,S., Einhorn, D., Grunberger, G., Handelsman, Y., Hennekens, C.H., Hurley, D.L., McGill, J., Palumbo, P., Umpierrez, G. American Association of Clinical Endocrinologist and American College of Endocrinology position statement on the advanced framework for a new diagnosis of obesity as a chronic disease. Endocrine practice. 2014; 20(9): 977-89.
Guh, D.P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C.L., Anis, A.H. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9(88): 1-20.
Iacobini C, Pugliese G, Fantauzzi CB, Federici M, Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2018;11(1):1-41.
Bagheri M, Farzadhfar F, Qi L, Yekaniejad MS, Chamari M, Zeleznik OA, et al. Obesity-related metabolomic profiles and discrimination of metabolically unhealthy obesity. J of Proteome Research. 2018; 3(1): 1-45.
Okita K, Nishijima H, Murakami T, Nagai T, Morita N, Yonezawa K et al. Can Exercise Training With Weight Loss Lower Serum C-Reactive Protein Levels? Aterioscler Thromb Vasc Biol. 2004; 24:1868-73.
Lavanya K, Ramamoorthi K, Acharya RV, Madhyastha SP. Association between Overweight, Obesity in Relation to Serum hs-CRP Levels in Adults 20-70 Years. Journal of Clinical and Diagnostic Research. 2017; 11(12): 32-5.
Ebrahimi M, Heidari-Bakavoli AR, Shoeibi S, et al. Association of Serum hs-CRP Levels With the Presence of Obesity, Diabetes Mellitus, and Other Cardiovascular Risk Factors. J Clin Lab Anal. 2016;30(5):672-6.
Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008; 168(15): 1617-24.
Blüher M. Metabolically Healthy Obesity. Endocr. Rev. 2020 1; 41(3): 1-5.
Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851-63.
Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol. 2018;9:754.
Devaraj S, Singh U, Jialal I. Jager et al. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):182-9.
Bennet, NR, Ferguson TS, Bennet FR, Reid MKT, Coleman NOMY, et al. High sensitivity C-Reactive Protein is related to central obesity and the number of metabolic syndrome components in Jamaican young adults. Frontiers in Cardiovascular Medicine.2014;12(1):1-10.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-334.
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2005;111(4): 210-217.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Jurnal Penyakit Dalam Udayana
This work is licensed under a Creative Commons Attribution 4.0 International License.